Updated Monday, 11/30. Five IPOs and two SPACs are scheduled for the week ahead, with a wave of Monday morning launches kicking off the December IPO blitz as expected. Chinese education technology group ...read more
Four IPOs are expected to raise $2 billion before the Fourth of July, led by commercial data analytics provider Dun & Bradstreet (DNB). Dun & Bradstreet (DNB) plans to raise $1.3 billion at a market cap of $8 billion. The...read more
Pliant Therapeutics, a Phase 2 biotech developing therapies for the treatment of fibrosis, raised $144 million by offering 9.0 million shares at $16, the high end of the $14 to $16 range. Earlier on Tuesday, Pliant filed an amendment adding 3.0...read more
IPOs are once again gaining steam and the calendar is flush with deals. With the IPO Index near all-time highs (tracked by NYSE: IPO), there are now eight offerings slated to price, making it...read more
US IPO Week Ahead: A flurry of launches forecasted to kick off December IPO blitz
Updated Monday, 11/30. Five IPOs and two SPACs are scheduled for the week ahead, with a wave of Monday morning launches kicking off the December IPO blitz as expected. Chinese education technology group ...read more
US IPO Week Ahead: Dun & Bradstreet returns to public market in shortened 4 IPO week
Four IPOs are expected to raise $2 billion before the Fourth of July, led by commercial data analytics provider Dun & Bradstreet (DNB). Dun & Bradstreet (DNB) plans to raise $1.3 billion at a market cap of $8 billion. The...read more
Fibrosis biotech Pliant Therapeutics prices IPO at $16 high end
Pliant Therapeutics, a Phase 2 biotech developing therapies for the treatment of fibrosis, raised $144 million by offering 9.0 million shares at $16, the high end of the $14 to $16 range. Earlier on Tuesday, Pliant filed an amendment adding 3.0...read more
This is the IPO market’s busiest week of the year with 8 deals on the calendar
IPOs are once again gaining steam and the calendar is flush with deals. With the IPO Index near all-time highs (tracked by NYSE: IPO), there are now eight offerings slated to price, making it...read more